Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
RHHVF Quote, Financials, Valuation and Earnings
Last price:
$466.14
Seasonality move
:
1.54%
Day range:
$462.62 - $480.00
52-week range:
$277.00 - $490.33
Dividend yield:
2.29%
P/E ratio:
24.97x
P/S ratio:
5.20x
P/B ratio:
6.80x
Volume:
25.3K
Avg. volume:
25.9K
1-year change:
44.63%
Market cap:
$381.9B
Revenue:
$74.1B
EPS (TTM):
$19.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$19.8B | -- | -- | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
GALDY
Galderma Group AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$480.00 | -- | $381.9B | 24.97x | $11.00 | 2.29% | 5.20x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1000 | -- | $7.9M | 5.90x | $0.00 | 0% | 0.61x |
|
GALDY
Galderma Group AG
|
$37.76 | -- | $44.3B | 130.29x | $0.03 | 0.04% | 9.58x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
53.53% | -0.533 | -- | 0.88x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.813 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.224 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.210 | -- | -- |
|
GALDY
Galderma Group AG
|
26.02% | 1.432 | -- | 0.80x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
GALDY
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHVF or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About RHHVF or BPMUF?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Roche Holding AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is RHHVF or BPMUF More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.835%.
-
Which is a Better Dividend Stock RHHVF or BPMUF?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.29%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or BPMUF?
Roche Holding AG quarterly revenues are --, which are smaller than Basilea Pharmaceutica AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than Basilea Pharmaceutica AG's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 24.97x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.20x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG5.20x 24.97x -- -- BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns RHHVF or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About RHHVF or CSBTF?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Roche Holding AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is RHHVF or CSBTF More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.678%.
-
Which is a Better Dividend Stock RHHVF or CSBTF?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.29%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or CSBTF?
Roche Holding AG quarterly revenues are --, which are smaller than Kuros Biosciences Ltd. quarterly revenues of --. Roche Holding AG's net income of -- is lower than Kuros Biosciences Ltd.'s net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 24.97x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.20x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG5.20x 24.97x -- -- CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns RHHVF or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About RHHVF or ELVAF?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than EvoNext Holdings SA, analysts believe Roche Holding AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is RHHVF or ELVAF More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.
-
Which is a Better Dividend Stock RHHVF or ELVAF?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.29%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ELVAF?
Roche Holding AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Roche Holding AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 24.97x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.20x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG5.20x 24.97x -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns RHHVF or GALDY?
Galderma Group AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Galderma Group AG's return on equity of 4.9%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B GALDYGalderma Group AG-- -- $10.4B -
What do Analysts Say About RHHVF or GALDY?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Galderma Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 GALDYGalderma Group AG0 0 0 -
Is RHHVF or GALDY More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison Galderma Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RHHVF or GALDY?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.29%. Galderma Group AG offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Galderma Group AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or GALDY?
Roche Holding AG quarterly revenues are --, which are smaller than Galderma Group AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than Galderma Group AG's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 24.97x while Galderma Group AG's PE ratio is 130.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.20x versus 9.58x for Galderma Group AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG5.20x 24.97x -- -- GALDYGalderma Group AG9.58x 130.29x -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 10.81% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 6.6% over the past day.
